[go: up one dir, main page]

PL2691109T3 - Zapobieganie hipoglikemii u pacjentów z cukrzycą typu 2 - Google Patents

Zapobieganie hipoglikemii u pacjentów z cukrzycą typu 2

Info

Publication number
PL2691109T3
PL2691109T3 PL12712106T PL12712106T PL2691109T3 PL 2691109 T3 PL2691109 T3 PL 2691109T3 PL 12712106 T PL12712106 T PL 12712106T PL 12712106 T PL12712106 T PL 12712106T PL 2691109 T3 PL2691109 T3 PL 2691109T3
Authority
PL
Poland
Prior art keywords
hypoglycaemia
patients
prevention
diabetes mellitus
mellitus type
Prior art date
Application number
PL12712106T
Other languages
English (en)
Inventor
Gabor Boka
Louise Silvestre
Patrick Miossec
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44504331&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2691109(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of PL2691109T3 publication Critical patent/PL2691109T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
PL12712106T 2011-03-29 2012-03-29 Zapobieganie hipoglikemii u pacjentów z cukrzycą typu 2 PL2691109T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11160270 2011-03-29
EP12712106.9A EP2691109B1 (en) 2011-03-29 2012-03-29 Prevention of hypoglycaemia in diabetes mellitus type 2 patients
PCT/EP2012/055660 WO2012130955A1 (en) 2011-03-29 2012-03-29 Prevention of hypoglycaemia in diabetes mellitus type 2 patients

Publications (1)

Publication Number Publication Date
PL2691109T3 true PL2691109T3 (pl) 2015-12-31

Family

ID=44504331

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12712106T PL2691109T3 (pl) 2011-03-29 2012-03-29 Zapobieganie hipoglikemii u pacjentów z cukrzycą typu 2

Country Status (19)

Country Link
US (2) US20120277147A1 (pl)
EP (1) EP2691109B1 (pl)
JP (1) JP6410600B2 (pl)
KR (1) KR20140033030A (pl)
CN (1) CN103582491B (pl)
AU (1) AU2012234180B2 (pl)
BR (1) BR112013024973B1 (pl)
CA (1) CA2830811A1 (pl)
CY (1) CY1116799T1 (pl)
DK (1) DK2691109T3 (pl)
ES (1) ES2549955T3 (pl)
HR (1) HRP20151087T1 (pl)
HU (1) HUE025716T2 (pl)
MX (1) MX336657B (pl)
PL (1) PL2691109T3 (pl)
PT (1) PT2691109E (pl)
RU (1) RU2583134C2 (pl)
SI (1) SI2691109T1 (pl)
WO (1) WO2012130955A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE068164T2 (hu) 2008-10-17 2024-12-28 Sanofi Aventis Deutschland Egy inzulin és egy GLP-1 agonista kombinációja
CA2780460C (en) 2009-11-13 2018-09-04 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
SG10201500871TA (en) 2009-11-13 2015-04-29 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
RS55378B1 (sr) 2010-08-30 2017-03-31 Sanofi Aventis Deutschland Upotreba ave0010 za proizvodnju leka za tretman diabetes mellitus tipa 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
BR112014004726A2 (pt) 2011-08-29 2017-04-04 Sanofi Aventis Deutschland combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
WO2015104311A1 (en) 2014-01-09 2015-07-16 Sanofi Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
SG11201604706TA (en) 2014-01-09 2016-07-28 Sanofi Sa Stabilized pharmaceutical formulations of insulin aspart
EP3091995B1 (en) 2014-01-09 2024-03-20 Sanofi Stabilized pharmaceutical formulations of insulin aspart
TWI758239B (zh) 2014-12-12 2022-03-21 德商賽諾菲阿凡提斯德意志有限公司 甘精胰島素/利司那肽固定比率配製劑
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
WO2020112253A2 (en) * 2018-10-16 2020-06-04 The Board Of Regents Of The University Of Oklahoma Uses of glucagon-like peptide-1 receptor agonists for treating trauma-induced hearing loss

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
SK287810B6 (sk) * 1999-11-03 2011-10-04 Bristol-Myers Squibb Company Farmaceutický prostriedok obsahujúci nízkodávkovú kombináciu metformínu a glyburidu
CN1413582A (zh) * 2002-11-29 2003-04-30 贵州圣济堂制药有限公司 盐酸二甲双胍肠溶片及其制备方法
WO2007001150A2 (en) * 2005-06-27 2007-01-04 Jae-Kwan Hwang Method for preventing and treating conditions mediated by ppar using macelignan
KR101368525B1 (ko) * 2005-09-20 2014-03-06 노파르티스 아게 저혈당 증상을 저하시키기 위한 ｄｐｐ-ⅳ 억제제의 용도
HUE068164T2 (hu) * 2008-10-17 2024-12-28 Sanofi Aventis Deutschland Egy inzulin és egy GLP-1 agonista kombinációja

Also Published As

Publication number Publication date
HK1192725A1 (en) 2014-08-29
ES2549955T3 (es) 2015-11-03
RU2583134C2 (ru) 2016-05-10
JP2014514289A (ja) 2014-06-19
BR112013024973B1 (pt) 2022-06-07
KR20140033030A (ko) 2014-03-17
MX336657B (es) 2016-01-27
MX2013011174A (es) 2013-11-01
AU2012234180A1 (en) 2013-10-17
JP6410600B2 (ja) 2018-10-24
CN103582491A (zh) 2014-02-12
RU2013148014A (ru) 2015-05-10
SI2691109T1 (sl) 2015-11-30
DK2691109T3 (en) 2015-10-19
HRP20151087T1 (hr) 2015-11-20
US20120277147A1 (en) 2012-11-01
AU2012234180B2 (en) 2017-02-16
WO2012130955A1 (en) 2012-10-04
CY1116799T1 (el) 2017-03-15
EP2691109B1 (en) 2015-07-15
BR112013024973A2 (pt) 2016-08-30
CN103582491B (zh) 2016-12-07
CA2830811A1 (en) 2012-10-04
EP2691109A1 (en) 2014-02-05
PT2691109E (pt) 2015-10-30
US20180000902A1 (en) 2018-01-04
HUE025716T2 (en) 2016-04-28

Similar Documents

Publication Publication Date Title
PT2691109E (pt) Prevenção de hipoglicemia em pacientes com diabetes mellitus tipo 2
IL232251B (en) Pharmaceutical combination for use in the treatment of type 2 diabetes patients
ZA201403795B (en) Formulations for the treatment of diabetes
PT2750699E (pt) Acelerómetro pendular
PT2779973T (pt) Interface de paciente com aplanação variável
PL2683395T3 (pl) Zastosowanie małych dawek il-2 do leczenia cukrzycy typu 1
SI2611458T1 (sl) Uporaba AVE0010 za izdelavo zdravila za zdravljenje sladkorne bolezni tipa 2
IL230957A0 (en) Pharmacy methods and preparations for the treatment of an eye disease in a patient
AP2014007399A0 (en) Phenyl-3-AZA-bicycloÄ3.1.0Ühex-3-YL-methanones andthe use thereof as medicament
AP2013007179A0 (en) Glycoside derivatives and their uses for the treatment of diabetes
IL223289A0 (en) Treatment of type 2 diabetes
GB201011095D0 (en) Improvements in or relating to ophthalmology
ZA201209701B (en) Improvements in or relating to ophthalmology
IL229591A0 (en) Addition of medicine
GB201011094D0 (en) Improvements in or relating to ophthalmology
EP2455090A4 (en) MEANS TO INHIBIT THE INCREASE OF THE POSTPRANDIAL BLOOD INSULIN MIRROR
PL2536400T3 (pl) Lek zawierający miramistin
PH12014501052A1 (en) Methods and compositions for the treatment of diabetes and related symptoms
EP2402342A4 (en) PHARMACEUTICAL COMPOSITION FOR TREATING TYPE 2 DIABETES
ZA201404738B (en) Treatment of type i and type ii diabetes
HK1190082A (en) Prevention of hypoglycaemia in diabetes mellitus type 2 patients
PT2717872T (pt) Combinação sinérgica para o tratamento da diabetes mellitus tipo 2
HK1193342A (en) Pharmaceutical combination for use in the treatment of diabetes type 2
IL232294A0 (en) Preparations for the treatment of diabetes
AU2011902031A0 (en) Improvements in medical treatment